Received Mar 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
second late dose; Patient had shingles November 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of shingles in a patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix and the 2nd dose of Shingrix. In NOV-2025, more than 2 years after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles (Verbatim: Patient had shingles November 2025). On an unknown date, the patient experienced incomplete course of vaccination (Verbatim: second late dose). The outcome of the shingles was not reported and the outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK Receipt Date: 09-MAR-2026 The pharmacist reported that a patient that requested Shingrix vaccination. The pharmacist mentioned there was a record of the patient receiving one dose of Shingrix back in 2021 in a different facility, however, this information does not match the state vaccination records and patient declined being vaccinated before with Shingrix. The patient had shingles in NOV-2025. Pharmacist requested medical information about Shingrix third dose safety and second late dose administration to make clinical decision on how to proceed. No third dose of Shingrix has been administered at the moment of the call. The batch number was not provided upon follow- up with the reporter.